Skip to content
eLearning on BoehringerOne
Visit BoehringerOne.com

HPN in CKD: Achieving Control Amidst the Pandemic?

Presenters

Dr. Richard Russell
Head of Cardiology and Heart Station Department
Romeo J. Santos, MD, FPCP, FPCC, FPSE, FACC
View Profile
Dr. Richard Russell
Chairman, Department of Internal Medicine
Renato Alagadan, MD, FPCP, FPCC
View Profile
Dr. Richard Russell
Associate Professor
Anna Guia Limpoco, MD, MSc, DFM, FPAFP
View Profile
Dr. Richard Russell
Associate Professor (ret.)
Froilan De Leon, MD, FPCP, FPSN
View Profile

  • 45 Mins

  • Self paced

    Upon completion you will earn a certificate

Start this course

Course Details

Hypertension is a major problem among patients with chronic kidney disease during the COVID-19 pandemic. In this CV Masterclass, Dr. Romeo Santos and a panel of experts discussed the multiple impacts of the COVID-19 pandemic on patients with hypertension and CKD and explained the role of RAS blockade in ensuring hypertension control and optimal renal outcomes during the pandemic.

Estimated time of Completion: 45 mins

CPD Points: 0.75 Point

PRC Program No: PROG-2022-41549

HPN in CKD: Achieving Control Amidst the Pandemic? Course Outline

  • Learning Objectives
  • Diabetes with Chronic Kidney Disease
  • Impact of COVID-19 pandemic on diabetes
  • HbA1c levels before/after Japan COVID-19 emergency declaration
  • HPN, DM and COVID-19 in the Philippines
  • DM and HPN control both needed to prevent CKD
  • Impact of COVID-19 pandemic on CKD
  • COVID-19 infection and kidney injury
  • Comprehensive management of CKD (e.g., CKD with DM and HPN)
  • ASN recommendations for DM with CKD (BP-lowering therapy)
  • ASN recommendations for DM with CKD (glucose-lowering)
  • 2020 ISH Simplified Classification of Hypertension Risk
  • Initiation of anti-hypertension treatment
  • High-risk Patients: Advantage of RAAS inhibitors
  • Unique “delta lock” structure of Telmisartan
  • Pharmacological Profile of Telmisartan
  • The Trough/Peak Ratio
  • Comparative Pharmacokinetic Profile
  • Telmisartan’s Long Duration of Effect
  • ONTARGET: Telmisartan as Effective as Ramipril in Preventing CV Events at Increased CV Risk 
  • Telmisartan versus Ramipril in renal ENdothelial DYsfunction study
  • Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study
  • telMisartan (80mg) vs. losArtan (100mg) in hypertensive type-2 DiabEtic patients with Overt nephropathy
  • Telmisartan is efficient along the renal continuum
  • Summary

PC-PH-103531 / September 2023